Aggregates in monoclonal antibody manufacturing processes.
about
Early implementation of QbD in biopharmaceutical development: a practical exampleImproving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsPassive immunization against HIV/AIDS by antibody gene transfer.Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics.Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.Multimodal chromatography: an efficient tool in downstream processing of proteins.Conformational stability as a design target to control protein aggregation.Thermal stability of high concentration lysozyme across varying pH: A Fourier Transform Infrared study.An intravaginal ring for the sustained delivery of antibodies.Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein.Antimicrobial preservatives induce aggregation of interferon alpha-2a: the order in which preservatives induce protein aggregation is independent of the proteinRole of benzyl alcohol in the unfolding and aggregation of interferon α-2a.Direct analysis of mAb aggregates in mammalian cell culture supernatant.Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.A polar ring endows improved specificity to an antibody fragment.Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs.A new approach to quantification of mAb aggregates using peptide affinity probes.Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic SequonApplication of the Protein Maker as a platform purification system for therapeutic antibody research and development.Rheology of clustering protein solutions.Acid-induced aggregation propensity of nivolumab is dependent on the Fc.Separation of proteins from human plasma by sample displacement chromatography in hydrophobic interaction mode.Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.Effect of antimicrobial preservatives on partial protein unfolding and aggregation.State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.Targeted drug delivery for cancer therapy: the other side of antibodies.New developments in lentiviral vector design, production and purification.A serendipitous survey of prediction algorithms for amyloidogenicity.Challenges and recent advances in affinity purification of tag-free proteins.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.A multiscale view of therapeutic protein aggregation: a colloid science perspective.Tailoring recombinant protein quality by rational media design.Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.Different fermentation processes produced variants of an anti-CD52 monoclonal antibody that have divergent in vitro and in vivo characteristics.A simple method to determine IgG light chain to heavy chain polypeptide ratios expressed by CHO cells.Cell culture media impact on drug product solution stability.The effects of arginine glutamate, a promising excipient for protein formulation, on cell viability: Comparisons with NaClRational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumabCharacterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs
P2860
Q26830466-BB915388-6575-4E7C-98DA-5181D3552339Q27002558-ACC82228-E45F-4944-A8E9-A18A95465966Q30358434-D587DBE7-48BC-41CA-B2D9-B156794ED496Q30384726-4E38CF5F-2BE4-49F2-A7BB-AE4603AA0B61Q30422151-2FF999A4-9C42-4BD0-B89E-282E557166A3Q30423377-EF5CEAA1-C097-4A3A-8186-61CEA65228FCQ30457837-D55963D7-0923-4937-97DC-D2C92CD93E5AQ34355995-CF8E7F08-C37B-4358-95D1-AC741F1B63AAQ34389166-AA638970-11E2-4E03-AE23-9E817F660E8AQ34545655-04AAF843-7E06-4962-A8E4-AD916C6657B8Q34715110-6AF0926D-308C-4EBA-B92C-A5CBB09FFE70Q35032786-6AD7BD0D-C01F-4655-B213-3FD458556103Q35457792-297CD43D-F92E-4299-B220-92E422BED079Q35918866-A52F54CC-D79C-49E8-967C-F4FAFD1183E8Q36059271-E6BC41FA-006C-49F3-82FA-28B8B78AF50EQ36213460-2ECE3220-9ED0-411F-85DF-4106367F2632Q36276715-2C77B712-CE6A-4442-ACD7-1AC431182E3CQ36855617-7FA654A4-547D-4562-9017-2A027A9BD5C4Q37063810-D9897436-20B1-446F-A955-CA207DEC49F5Q37099154-134675E1-CD93-4854-BF24-625672F80AC3Q37141601-4035C1E9-6DA1-4E65-A36E-DD32E0682E81Q37252511-FCA4BE68-76A8-4266-ADE3-6E2D50DE17A0Q37530217-A1385573-CC8A-4207-8662-B9B721B10135Q37708774-F968EDDE-6771-485C-8F0B-42ACADA41554Q38013999-ED1DBD1C-6E62-4A87-ADCD-C2AEFF61FED6Q38058816-3BA589F2-FB41-4AEE-A9F3-0AF7CCFB8AD7Q38099382-41F04868-17ED-4F53-94D1-FB3818831907Q38124811-5B605127-895A-4D04-B1D9-77181CF62A54Q38198528-8BDD68DC-F9F3-4D97-B45B-558EE269AA63Q38202541-9A7D4AE6-F147-4C80-8BC7-E2226770CDECQ38365744-C81E5335-09E3-4D51-A5BF-C145F30BAACEQ38378651-E4B23B10-F14D-45F9-AAC9-EA5711473E7BQ38416739-5A0E9793-A93B-4BDF-8398-7310C8472770Q38678186-FB811A6A-874D-480C-9861-C80B0572602CQ38703253-E52FBF77-80FB-499B-8ECA-44F354230249Q38738521-35DF0685-2A5D-4FD9-AF92-27A183A6DE99Q38775603-D9C068E8-4B85-4C7E-8E1F-192FCE6C58EFQ38794404-F342B4E3-69F3-464A-88D8-47F93B7A0D8DQ38823875-8A3049E9-393A-40C5-9217-07275D38CF9DQ38887796-51179492-C67E-4D32-81EB-6D1666DCB8F6
P2860
Aggregates in monoclonal antibody manufacturing processes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aggregates in monoclonal antibody manufacturing processes.
@en
Aggregates in monoclonal antibody manufacturing processes.
@nl
type
label
Aggregates in monoclonal antibody manufacturing processes.
@en
Aggregates in monoclonal antibody manufacturing processes.
@nl
prefLabel
Aggregates in monoclonal antibody manufacturing processes.
@en
Aggregates in monoclonal antibody manufacturing processes.
@nl
P2860
P356
P1476
Aggregates in monoclonal antibody manufacturing processes.
@en
P2093
Dietmar A Lang
María Vázquez-Rey
P2860
P304
P356
10.1002/BIT.23155
P577
2011-04-20T00:00:00Z